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Edited by Gianni CesareniAbstract Hypoxia-inducible factor-1 (HIF) is regulated by
oxygen-dependent prolyl hydroxylation. Of the three HIF prolyl
hydroxylases (PHD1, 2 and 3) identiﬁed, PHD3 exhibits
restricted substrate speciﬁcity in vitro and is induced in diﬀerent
cell types by diverse stimuli. PHD3 may therefore provide an
interface between oxygen sensing and other signalling pathways.
We have used co-puriﬁcation and mass spectrometry to identify
proteins that interact with PHD3. The cytosolic chaperonin
TRiC was found to copurify with PHD3 in extracts from several
cell types. Our results indicate that PHD3 is a TRiC substrate,
providing another step at which PHD3 activity may be
regulated.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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chaperonin1. Introduction
Hypoxia-inducible factor (HIF) plays a key role in mediat-
ing cellular responses to oxygen [1]. HIF itself is regulated by
oxygen-dependent hydroxylation of speciﬁc amino acids
within HIF-a subunits [2]. Asparaginyl hydroxylation medi-
ated by factor inhibiting HIF-1 (FIH-1) [3] regulates HIF
transactivation, while prolyl hydroxylation regulates degra-
dation of HIF-a chains. HIF-1a and HIF-2a each possess two
oxygen-dependent degradation domains (ODD), denoted
NODD and CODD (for N- and C-terminal ODD [4]), con-
taining the prolyl residues essential for oxygen-dependent
regulation (residues 402 and 564 in human HIF-1a). In
mammals three HIF-prolyl hydroxylases have been identiﬁed
(denoted PHD1, 2 and 3) that oxidise these prolines to the
corresponding trans-4-hydroxyproline residues [5,6], leading to
ubiquitylation by the von Hippel–Lindau (VHL) E3 ubiquitin
ligase and degradation. Like FIH, the PHD enzymes are
members of the Fe(II)- and 2-oxoglutarate-dependent di-
oxygenase superfamily. The relative importance of each PHD* Corresponding author. Fax: +44-01865-287533.
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though one study suggests that PHD2 is critical for achieving
the normally low steady state levels of HIF-1a in normoxia [7].
Studies of the PHDs in vitro indicate diﬀerences in substrate
speciﬁcity with PHD3 unable to hydroxylate the NODD [6,8].
The PHD’s also diﬀer in their tissue distributions [9,10] and, at
least under conditions of overexpression, have distinct patterns
of subcellular localisation [11,12]. Inducibility of the PHD
genes also varies. For instance, both PHD2 and PHD3
mRNAs are induced by hypoxia [6,13,14], PHD1 mRNA has
been reported to be oestrogen-inducible [15] and PHD3 has
been identiﬁed as a gene induced by p53 [16], by stimuli in-
ducing smooth muscle diﬀerentiation [17,18] and by nerve
growth factor withdrawal [19].
Given the inducibility of PHD3 by various stimuli (including
hypoxia) and its restricted substrate speciﬁcity for the HIF-a
CODD, we have sought to understand more about the cellular
regulation of PHD3. As an initial approach, we have identiﬁed
a set of 50–60 kDa polypeptides that copurify with PHD3 from
cell extracts. These proteins correspond to subunits of the
cytosolic chaperonin TRiC (TCP-1 ring complex, also called
CCT, for chaperonin containing TCP-1). The interaction be-
tween PHD3 and TRiC appears to be speciﬁc to this particular
HIF hydroxylase and was stabilised by EDTA, suggesting that
PHD3 is a TRiC substrate.2. Materials and methods
2.1. Plasmids and in vitro translation
PHD1PK, PHD2PK, PHD3PK and FIHPK expression vectors were
constructed in pcDNA3. pUHD10 [20] was used to make the tet-op-
erator-dependent PHD3PK expression plasmid. [35S]Methionine-la-
belled proteins were generated in TNT reticulocyte lysate (Promega).
For the EDTA pulse chase experiment, PHD3PK was translated for 15
min at 30 C, cycloheximide was then added (2 mM ﬁnal concentra-
tion) and the mixture incubated for a further 40 min with or without
EDTA (5 mM ﬁnal concentration).
2.2. Cell culture, transient and stable transfections
HeLa and HEK 293T cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium with 10% foetal calf serum, glutamine (2 mM), peni-
cillin (50 IU/ml) and streptomycin sulfate (50 lg/ml). For metabolic
labelling, cells were pre-incubated for 1 h in serum-free medium,
lacking methionine and cysteine followed by incubation for 5 h in
medium containing 250 lCi/ml [35S]methionine/cysteine (Pro-mix,
Amersham Biosciences). Transient transfections were performed usingblished by Elsevier B.V. All rights reserved.
Fig. 1. PHD3PK associates with a set of 50–60 kDa proteins in vivo. (A)
HeLa cells were transiently transfected with empty vector (control),
PHD1PK or PHD3PK as indicated. Cells were labelled with
[35S]methionine, lysed and analysed by immunoprecipitation with anti-
PK antibody. Captured proteins were resolved by 10% SDS–PAGE and
detected by ﬂuorography. The 50–60 kDa PHD3PK-associated pro-
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stable cell line, U20S cells bearing the reverse tetracycline responsive
transactivator [20] and a tetKRAB silencer construct [21] were trans-
fected with pUHD10-PHD3PK plasmid and colonies picked after se-
lection in hygromycin B (200 lg/ml). The cell line was maintained in
medium containing 10% Tet System approved FBS (BD Biosciences),
hygromycin B (200 lg/ml), and blasticidin S (5 lg/ml). PHD3PK ex-
pression was induced by administration of doxycycline (0.1 lg/ml).
Hypoxic incubations were performed in a Napco 7001 incubator
(Jouan).
2.3. Antibodies, immunoprecipitation and immunoblotting
Anti PK-tag (sv5-pk) (Serotec), anti-TCP-1a (91a) (Calbiochem)
and anti-HIF-1a antibody (Transduction Laboratories clone 54) were
used. Monoclonal antibodies to PHD2 and PHD3 produced in this
laboratory will be described elsewhere (Y. Tian unpublished). Cell
extracts were prepared under denaturing conditions (8 M urea, 10%
glycerol, 1% SDS, 1 mM DTT, and 10 mM Tris, pH 6.8), or in NP-
40 lysis buﬀer [10 mM Tris, pH 7.5, 0.25 M NaCl, and 0.5% NP-40
with ‘‘Complete’’ Protease inhibitor (Roche Molecular Biochemi-
cals)]. For immunoprecipitation, cell extract was pre-cleared for 1 h
at 4 C with Protein G–Sepharose beads. Samples were incubated
with antibody at 4 C for 1 h followed by 2 h incubation with Protein
G–Sepharose. Beads were washed ﬁve times in Wash Buﬀer (125 mM
NaCl, 25 mM Tris, pH 7.5, and 0.1% NP-40). Following SDS–
PAGE, proteins were Coomassie stained, or transferred onto
Immobilon-P membrane (Millipore) and immunoblotted. [35S]methi-
onine-labelled proteins were ﬁrst diluted (10 ll reticulocyte lysate
diluted to 500 ll with NP-40 lysis buﬀer) prior to addition of anti-
body and immunoprecipitation as above.
2.4. MALDI-MS protein identiﬁcation
Protein bands were digested in-gel using 5 ll of 12 ng/mL porcine
trypsin (Promega). Tryptic peptides were then desalted and concen-
trated on chromatographic beads [22] consisting of Poros R2 material
(Boehringer Mannheim) prior to analysis by MALDI-TOF mass
spectrometry using a REFLEX MALDI-TOF mass spectrometer
(Bruker–Daltonik) operating in reﬂectron mode. Peptide mass ﬁnger-
prints were analysed using the Mascot algorithm (http://www.matrix-
science.com), using a peptide mass tolerance of 0.3 Da. Unidentiﬁed
peptides were subjected to MALDI-PSD analysis and fragmentation
spectra analysed with the Mascot algorithm using a fragment mass
tolerance of 0.8 Da.teins are indicated by an asterisk. (B) PHD3PK cells were either un-
treated ()) or induced (+) with doxycycline (Dox) for 20 h, followed by
exposure to normoxic (21% O2) or moderate hypoxic (2.7% O2) con-
ditions for 4 h. Extracts were prepared under denaturing conditions and
analysed by immunoblotting. (C) PHD3PK cells were either untreated
()) or induced (+) with doxycycline (Dox) for 24 h as indicated, fol-
lowed by [35S]methionine-labelling, harvest and immunoprecipitation
with anti-PK antibody. The position of the PHD3PK protein is shown
and the copurifying 50–60 kDa proteins marked with an asterisk.3. Results and discussion
To identify proteins that interact with PHD enzymes, a co-
immunopuriﬁcation approach was adopted (Fig. 1A). A set of
50–60 kDa polypeptides were found to copurify with
PHD3PK but not with PHD1PK following transient trans-
fection of expression plasmids into HeLa cells.
To maximise the potential for successful identiﬁcation of the
PHD3-associated proteins, a doxycycline-inducible stable
PHD3PK U20S cell line was made. Anti-PK immunoblottting
conﬁrmed doxycycline-inducible expression of PHD3PK
(Fig. 1B). Parallel immunoblottting with anti-HIF-1a antibody
established that the overexpressed PHD3PK enzyme was
functional, signiﬁcantly reducing HIF-1a protein level induced
by hypoxia and even the basal level in normoxia (Fig. 1B).
Finally, [35S]methionine-labelling and anti-PK immunopre-
cipitation conﬁrmed that association between PHD3PK and
the set of 50–60 kDa polypeptides also occurred in this cell line
(Fig. 1C).
To identify the copurifying proteins, large-scale puriﬁcations
were performed from the PHD3PK inducible stable cell line.
Coomassie-staining (Fig. 2A) was suﬃcient to reveal a set of
50–60 kDa polypeptides copurifying with PHD3PK (consist-
ent with 35S-labelling, Fig. 1A and C). The identity of theseproteins was determined by mass spectrometry. A match to the
TRiC subunit, TCP-1c, was obtained with the 55 kDa band
(Fig. 2B). The 60 kDa band appeared to be a mixture of
proteins with the Mascot algorithm unable to clearly identify
any protein (Supplementary Data). However, the analysis did
yield some hits to the TRiC subunits TCP-1a; h; e, and b. To
gain further clariﬁcation on the 60 kDa band, the major pep-
tide 1150.57 was subjected to MALDI-PSD analysis (Fig. 2C)
conﬁrming the presence of TCP-1h subunit in the protein
mixture of the 60 kDa band. Immunoblotting was then used to
demonstrate association of PHD3 with the TCP-1a TRiC
subunit (Fig. 2D). These results demonstrate that PHD3
interacts with at least three subunits of TRiC in U20S cell
extracts (TCP-1c and h by mass spectrometric analyses and
TCP-1a by immunoblotting). To ensure that association of
TRiC with PHD3PK was not an artefact of the PK-tag, native
PHD3 was transiently overexpressed in HEK 293T cells and
immunoprecipitated with a PHD3 speciﬁc antibody (Fig. 2D).
Fig. 2. Identiﬁcation of the TRiC chaperonin as a PHD3 associated complex in U20S cells. (A) The PHD3PK inducible stable cell line was either
mock treated ()) or induced with doxycycline (+). Cell lysates were immunoprecipitated with anti-PK antibody, resolved by 10% SDS–PAGE and
retrieved proteins stained with Coomassie blue. The anti-PK immunoprecipitates revealed a doxycycline-inducible band with the expected mobility
for PHD3PK. This assignment was conﬁrmed by immunoblotting and mass spectrometric analysis (data not shown). The positions of the heavy and
light chain (resulting from the anti-PK antibody) are shown. PHD3PK co-precipitating proteins are indicated by the asterisk and include a major
band at 60 kDa. (B) The 55 kDa PHD3PK-associated band from U20S extracts (Fig. 2A) was excised, digested in-gel with trypsin and analysed by
MALDI-TOF. Using the Mascot algorithm, the labelled peptides from the 55 kDa band were identiﬁed as tryptic peptides from (P49368) TCP-1c
subunit with a score of 34 and 8% sequence coverage. C, The PSD analysis of peptide 1150.42 in the 60 kDa band. The fragmentation pattern was
identiﬁed by Mascot as originating from the peptide FAEAFEAIPR with a score of 21. D, the PHD3PK inducible stable cell line was either mock
treated ()) or induced with doxycycline (‘‘Dox’’, +). Cell extracts were either analysed directly, or immunoprecipitated with anti-PK antibody, prior
to 10% SDS–PAGE and immunoblotting with TCP-1a antibody. 293T cells were either mock transfected ()) or transfected (+) with PHD3 plasmid.
40h after transfection, extracts were immunoprecipitated using anti-PHD3 antibody. The position of the interacting TCP-1a protein is shown.
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native PHD3 and TRiC. To address whether the PHD3–TRiC
interaction observed in transfected cells occurred because of
PHD3 overexpression, association was analysed following
synthesis of PHD3 in reticulocyte lysate. In vitro translation
produces very low concentrations of protein (fM-pM) that are
vastly lower than the concentration of TRiC in the lysate (lM
range, [23]). All four HIF hydroxylases were synthesised in
reticulocyte lysate and assayed for association with TRiC by
immunoblotting with anti-TCP-1a antibody (Fig. 3A). Asso-
ciation with TRiC appears to be speciﬁc to the PHD3 enzyme,
since no interaction was seen with PHD1, PHD2 or FIH in this
system.
Since the immunoprecipitation conditions used would not
be expected to disrupt the TRiC chaperonin, it appears thatFig. 3. PHD3 is a speciﬁc substrate of TRiC in reticulocyte lysate. (A)
PHD1PK, PHD2PK, PHD3PK and FIHPK proteins were synthesised
in reticulocyte lysate and immunopuriﬁed using either anti-PK anti-
body (PHD1PK, PHD3PK and FIHPK) or anti-PHD2 antibody
(PHD2PK). The immunopuriﬁed proteins were analysed by 15% SDS–
PAGE (INPUTS) to check recovery. Immunoprecipitates normalised
for PHD/FIH protein level were then resolved on 10% SDS–PAGE and
immunoblotted with TCP-1a antibody. The position of the TCP-1a
protein is shown. (B) The eﬀect of EDTA on PHD3-TCP-1a associa-
tion in reticulocyte lysate was studied. 35S-labelled PHD3PK was
translated for 15 min at 30 C, cycloheximide was added and the
mixture further incubated in the presence or absence of 5 mMEDTA as
indicated. PHD3PK was then immunopuriﬁed using anti-PK antibody
and recovery checked by autoradiography (INPUTS). Immunopre-
cipitates normalised for PHD3PK protein were then immunoblotted
with anti-TCP-1a antibody.PHD3 is binding to the holo-TRiC complex. TRiC is a large
(900 kDa) cylindrical double ring complex, with each ring
consisting of 8 homologous subunits. It binds non-native
polypeptides in its central cavity and mediates folding and
release in a Mg2þ/ATP-dependent manner [24,25]. The
ability to purify Coomassie-stainable levels of TRiC with
PHD3 (Fig. 2A) indicates that TRiC is likely to be a reg-
ulator rather than a substrate of PHD3. To determine
whether TRiC may be required for PHD3 folding, protein
association was studied in a pulse chase experiment in the
presence or absence of EDTA (Fig. 3B). Newly translated
PHD3 was found associated with TRiC but was released
during the subsequent chase. In contrast, addition of EDTA
to the chase mixture stabilised the PHD3–TRiC association,
suggesting that as with other TRiC substrates, Mg2þ/ATP is
required. TRiC-bound proteins include binding partners [26]
as well as substrates. A limited number of TRiC substrates
have been identiﬁed which include cytoskeletal proteins such
as actin, a- and b-tubulin, and signalling proteins such as G
a-transducin and cyclin E [27]. Known TRiC substrates
appear to have either aggregation-prone folding intermedi-
ates or a requirement for binding to an oligomeric partner(s)
to complete folding [27]. It is likely that PHD3 conforms to
the former class of substrates, since overexpression of PHD3
(and not the other HIF hydroxylases) in mammalian cells is
known to result in aggregates [12] and immunoprecipitations
from 35S-labelled cell lysates did not reveal any evidence of a
PHD3 multiprotein enzyme complex, only the association
with TRiC (Fig. 1A and C).
TRiC has been proposed to play a speciﬁc role in the
formation of enzymatically active multiprotein complexes
[28,29], including the VHL/elongin B/C complex [30–32]. The
identiﬁcation of PHD3 as a novel TRiC substrate raises
questions as to whether interplay may exist between PHD3–
TRiC and VHL–TRiC complexes in vivo, which may impact
upon HIF regulation. Endogenous PHD3 protein is ex-
pressed at low levels under normoxic conditions but is in-
duced by hypoxia (Y. Tian et al., unpublished) and PHD3
mRNA is also known to be induced in diﬀerent cell types by
a range of other stimuli [16–19]. In the future, it will be of
interest to determine whether the induction of PHD3 protein
in vivo has any eﬀect on VHL–TRiC association and the
extent of cross-talk between these interactions in direct re-
sponses to hypoxia.Acknowledgements: We thank Judith Frydman and Jonathan Gleadle
for helpful discussion and the Medical Research Council, Wellcome
Trust, Ghent University Concerted Research Actions (GOA) and the
National Research Fund-Flanders for ﬁnancial support.References
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